United Health (UNH Stock) Q2 earnings: Weak estimates but history supports a beat
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFERUnited Health Group Inc (#UnitedHealth ) is the second-largest healthcare company in the world and the most diversified healthcare company in the US; it provides a wide range of healthcare products and services like healthcare coverage and benefits services and also applies technologies to improve access to health and wellbeing services through its 4 subsidiaries – UnitedHealthcare, OptumHealth, OptumInsight, and OptumRX – with over 330,000 employees across the world. Ranked 5th in the Fortune 500 with a market cap of $384.66B, the health care giant is set to release its Q2 2021 earnings report this Thursday (July 15) before the market opens.
#UnitedHealth is expected to post quarterly earnings of $4.40 EPS, down 38.2% y/y, and revenue of $69.55B, up 11.9% y/y, according to Zack’s consensus estimate. Despite this mixed expectation and Zack’s Most Accurate Estimate unchanged at $4.40 EPS, indicating no revisions by analysts, the company has managed to maintain a #2 buy on the Zack ranking. Over the last 4 quarters, #UNH has beaten the consensus Earnings/share every single time, with the latest release beating estimates by 20.14% ($5.31 EPS against $4.42 EPS expected),, which puts focus on the deviation from expectation for the release. Although the unprecedented amount of monetary stimulus and low-interest rates should prove supportive for companies like #UnitedHealth, 22 analysts from Yahoo finance research estimate a buy and strong buy bias on the share price while Trefis values the 44-year-old company at $422, above the current market price.
Technically, #UnitedHealth maintains a bullish trend, having risen almost 16% from 2020 highs to create a fresh ATH around $425; it is currently trading around $416 (above the 20 SMA and 50 SMA). May highs at $418 serve as the immediate resistance level and if broken, the $425 ATH will be the next stop if expectations are beaten by a good variance. Technically, the next key Fibonacci levels the 261.8 (from the January-February decline) and the 161.8 (from the May-June decline) create a new target zone $445-453.
On the other hand, a miss in the numbers could see the share price dip from these high levels – an excuse for profit-taking – towards the 20 SMA and 50.0-38.2 Fib zone at $405-400. Below here is the June low at $385, the April low at $360, and the 2021 low from February at $320.
United Health Group Inc (#UnitedHealth ) is the second-largest healthcare company in the world and the most diversified healthcare company in the US; it provides a wide range of healthcare products and services like healthcare coverage and benefits services and also applies technologies to improve access to health and wellbeing services through its 4 subsidiaries – UnitedHealthcare, OptumHealth, OptumInsight, and OptumRX – with over 330,000 employees across the world. Ranked 5th in the Fortune 500 with a market cap of $384.66B, the health care giant is set to release its Q2 2021 earnings report this Thursday (July 15) before the market opens.
#UnitedHealth is expected to post quarterly earnings of $4.40 EPS, down 38.2% y/y, and revenue of $69.55B, up 11.9% y/y, according to Zack’s consensus estimate. Despite this mixed expectation and Zack’s Most Accurate Estimate unchanged at $4.40 EPS, indicating no revisions by analysts, the company has managed to maintain a #2 buy on the Zack ranking. Over the last 4 quarters, #UNH has beaten the consensus Earnings/share every single time, with the latest release beating estimates by 20.14% ($5.31 EPS against $4.42 EPS expected),, which puts focus on the deviation from expectation for the release. Although the unprecedented amount of monetary stimulus and low-interest rates should prove supportive for companies like #UnitedHealth, 22 analysts from Yahoo finance research estimate a buy and strong buy bias on the share price while Trefis values the 44-year-old company at $422, above the current market price.
Technically, #UnitedHealth maintains a bullish trend, having risen almost 16% from 2020 highs to create a fresh ATH around $425; it is currently trading around $416 (above the 20 SMA and 50 SMA). May highs at $418 serve as the immediate resistance level and if broken, the $425 ATH will be the next stop if expectations are beaten by a good variance. Technically, the next key Fibonacci levels the 261.8 (from the January-February decline) and the 161.8 (from the May-June decline) create a new target zone $445-453.
On the other hand, a miss in the numbers could see the share price dip from these high levels – an excuse for profit-taking – towards the 20 SMA and 50.0-38.2 Fib zone at $405-400. Below here is the June low at $385, the April low at $360, and the 2021 low from February at $320.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.